Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    15867204 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1
Condition: Diffuse Large-Cell Lymphoma
Interventions: Drug: rituximab;   Drug: doxorubicin;   Drug: cyclophosphamide
2 Unknown  ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell Lymphoma
Interventions: Drug: rituximab;   Drug: doxorubicin;   Drug: cyclophosphamide;   Procedure: autologous stem cell transplantation
3 Terminated ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell Lymphoma
Interventions: Drug: rituximab;   Drug: doxorubicin;   Drug: cyclophosphamide
4 Recruiting Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Rituximab+mVPDL
5 Terminated Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Intervention: Drug: MK2206
6 Unknown  R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell Lymphoma
Interventions: Drug: R-CHOP21;   Drug: R-CHOP14;   Drug: Darbepoetin alfa

Indicates status has not been verified in more than two years